- Home
- PCYO vs CRDF Comparison
PCYO vs CRDF Comparison
Compare PCYO & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- CRDF
- Stock Information
- Founded
- PCYO 1976
- CRDF 1999
- Country
- PCYO United States
- CRDF United States
- Employees
- PCYO N/A
- CRDF N/A
- Industry
- PCYO Water Supply
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCYO Utilities
- CRDF Health Care
- Exchange
- PCYO Nasdaq
- CRDF Nasdaq
- Market Cap
- PCYO 271.7M
- CRDF 288.7M
- IPO Year
- PCYO N/A
- CRDF N/A
- Fundamental
- Price
- PCYO $11.49
- CRDF $4.75
- Analyst Decision
- PCYO
- CRDF Strong Buy
- Analyst Count
- PCYO 0
- CRDF 3
- Target Price
- PCYO N/A
- CRDF $10.33
- AVG Volume (30 Days)
- PCYO 35.5K
- CRDF 971.7K
- Earning Date
- PCYO 04-09-2025
- CRDF 02-27-2025
- Dividend Yield
- PCYO N/A
- CRDF N/A
- EPS Growth
- PCYO 103.72
- CRDF N/A
- EPS
- PCYO 0.55
- CRDF N/A
- Revenue
- PCYO $29,113,000.00
- CRDF $688,000.00
- Revenue This Year
- PCYO N/A
- CRDF $25.03
- Revenue Next Year
- PCYO N/A
- CRDF N/A
- P/E Ratio
- PCYO $20.89
- CRDF N/A
- Revenue Growth
- PCYO 56.25
- CRDF 49.57
- 52 Week Low
- PCYO $8.94
- CRDF $1.65
- 52 Week High
- PCYO $14.63
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- PCYO 43.48
- CRDF 62.77
- Support Level
- PCYO $11.23
- CRDF $4.12
- Resistance Level
- PCYO $12.25
- CRDF $4.38
- Average True Range (ATR)
- PCYO 0.28
- CRDF 0.38
- MACD
- PCYO 0.03
- CRDF 0.04
- Stochastic Oscillator
- PCYO 25.49
- CRDF 80.17
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. It designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The company's services include water production, storage, treatment, bulk transmission to retail distribution systems, wastewater collection and treatment, irrigation water treatment and transmission, construction management, billing, and collection. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").